Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate
Individualized High Dose Methotrexate for the Treatment of Malignancies in Children and Adolescents With a Significant Risk for Methotrexate Toxicities
Sponsor: Baylor College of Medicine
A NA clinical study on Cancer, this trial is completed. The trial is conducted by Baylor College of Medicine and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
-
Mar 2021 — Dec 2022 [monthly]
Completed NA
Status: Unknown Status → Completed
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Unknown Status NA
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Dec 2019 [monthly]
Active Not Recruiting NA
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Dec 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Texas Children's Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .